| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 18.00 | 0.00 (0.00%) | 15.01 - 21.16 | 25.8 thousand |
Market data as of 4:00PM 05/17/13. Quotes are delayed by at least 15 min.
| Open | 18.02 |
|---|---|
| Previous Close | 18.00 |
| Day's Range | 17.95 - 18.15 |
| Market Cap | 241.6M |
| Avg Volume (10 Day) | 24.6K |
| Price/Earnings (Trailing 12 Mo.) | 18.0x |
| Earnings Per Share (Trailing 12 Mo.) | 1 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Pass |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Pass |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Pass |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Exactech Launches GibraltĀ® OCT Spinal System for Complex Cervical Thoracic Spine Procedures Now Offering Spinal Fusion Solutions For The Entire Spine
Business Wire - Monday 05/06/2013 9:45 AM ET
Exactech Q1 Net Income up 17% to $3.8 Million; Diluted EPS $.29 vs. $.25; Worldwide Sales Up 1% to $59.3 Million; U.S. Sales Increased 6%
Business Wire - Tuesday 04/23/2013 4:01 PM ET
| EXAC | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 6.81% | |
| Net Income Growth (1yr) | 176.31% | |
| Total Debt/Equity | 0.23 | |
| LT Debt/Equity | 0.22 | |
| Earnings Yield | 5.56% | |
| Price/Sales | 1.07 |
| Company | Last | Change |
|---|---|---|
| RTI Biologics Inc | 4.33 | -1.14% |
| Palomar Medical Technologies Inc | 13.56 | +0.15% |
| Navidea Biopharmaceuticals Inc | 2.39 | +1.70% |
| ZELTIQ Aesthetics Inc | 4.95 | +5.32% |
| CryoLife Inc | 6.34 | +0.48% |
Data is delayed by at least 15 min.